KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Investment Income: 2021-2022

  • Xenon Pharmaceuticals' Non Operating Investment Income fell 7476.47% to -$1.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was -$4.7 million, marking a year-over-year change of. This contributed to the annual value of -$719,000 for FY2021, which is 18075.00% down from last year.
  • Xenon Pharmaceuticals' Non Operating Investment Income amounted to -$1.3 million in Q2 2022, which was up 61.69% from -$3.4 million recorded in Q1 2022.
  • Over the past 5 years, Xenon Pharmaceuticals' Non Operating Investment Income peaked at -$17,000 during Q2 2021, and registered a low of -$3.4 million during Q1 2022.
  • In the last 2 years, Xenon Pharmaceuticals' Non Operating Investment Income had a median value of -$681,000 in 2021 and averaged -$1.2 million.
  • Data for Xenon Pharmaceuticals' Non Operating Investment Income shows a maximum YoY plummeted of 7,476.47% (in 2022) over the last 5 years.
  • Over the past 2 years, Xenon Pharmaceuticals' Non Operating Investment Income (Quarterly) stood at -$17,000 in 2021, then slumped by 7,476.47% to -$1.3 million in 2022.
  • Its last three reported values are -$1.3 million in Q2 2022, -$3.4 million for Q1 2022, and -$17,000 during Q2 2021.